13 Chinese Private Pharmaceutical Manufacturers Listed in China's Top 500 Private Enterprises; Several File IPO Prospectuses

　　【Pharmaceutical Network - Industry Dynamics] On August 22, the “2019 Top 500 Chinese Private Enterprises” list, released by the All-China Federation of Industry and Commerce, was unveiled. Huawei topped the list for the fourth consecutive year, while HNA Group and Suning Holdings Group ranked second and third, respectively.
 

The Top 500 Private Enterprises in China list is compiled based on the All-China Federation of Industry and Commerce’s survey of large-scale private enterprises, with voluntary applications submitted by the enterprises, reviewed by the All-China Federation of Industry and Commerce, and ranked in descending order by operating revenue. Compared to last year, the threshold for inclusion in the Top 500 Private Enterprises has risen from RMB 15.684 billion to RMB 18.586 billion.
 

In the pharmaceutical sector, a total of 13 pharmaceutical manufacturing companies made it into the Top 500 list. This number remains unchanged from last year; however, there is a downward trend in the overall rankings of pharmaceutical companies this year. Notably, Kangmei Pharmaceutical Co., Ltd dropped from its previous position of 278th to 475th, with an operating revenue of RMB 19.356 billion in 2018.
 

Among the 13 pharmaceutical companies listed in the Top 500 Private Enterprises, Jointown Pharmaceutical Group ranks 67th; Correction Pharmaceutical Group Co., Ltd. ranks 109th; Shenzhen Neptunus Group Co., Ltd. ranks 141st; Weigao Group ranks 169th; Sichuan Kelun Industry Group ranks 189th; Huadong Medicine Co., Ltd. ranks 274th; CSPC Pharmaceutical Group Limited ranks 283rd; Tasly Holding Group Co., Ltd. ranks 290th; Wuhan Dangdai Technology Industry Group Co Ltd ranks 304th; Jemincare ranks 410th; Shandong Qilu Pharmaceutical Group Co., Ltd. ranks 414th; Changjiang Runfa Group Co., Ltd. ranks 444th; and Kangmei Pharmaceutical Co., Ltd. ranks 475th.
 

Compared with last year’s list, Shandong Haiwang Galaxy Pharmaceutical Co., Ltd. and Yangtze River Pharmaceutical Group dropped out of the list, while Changjiang Runfa and CSPC newly entered the list.
 

Among the top three private pharmaceutical manufacturing enterprises, Jointown Pharmaceutical Group ranked67position, rising one place from last year; followed by Correction Pharmaceutical Group Co.,Ltd. at 109th, a drop of 20 places from last year; and Neptunus Group at 141st, up one place from last year.
 

　　Jointown Pharmaceutical Group: Revenue Reaches RMB 87.1 Billion
 

Among them, Jointown Pharmaceutical Group ranked first among private enterprises in the pharmaceutical manufacturing industry. According to Jointown's announcement, it achieved an operating revenue of RMB 87.136 billion in 2018, a year-on-year increase of 17.84%; the net profit attributable to shareholders of the listed company was RMB 1.341 billion, a year-on-year decrease of 7.26%.
 

Publicly available information indicates that Jointown Pharmaceutical Group is a joint-stock enterprise whose core businesses include the wholesale, logistics and distribution, retail chain operations, and e-commerce of Western medicines, traditional Chinese medicines, and medical devices.
 

　　Correction Pharmaceutical: Revenue Exceeds 60 Billion
 

Correction Pharmaceutical Group Co.,Ltd. has generated over RMB 60 billion in revenue over the past three years, firmly securing its position on the “Top 100 Chinese Pharmaceutical Industry Companies” list. The company aims to achieve annual sales revenue of RMB 100 billion within ten years and reach RMB 1 trillion by 2030, thereby becoming one of the top 100 pharmaceutical companies worldwide.
 

Public information indicates that Correction Pharmaceutical Group Co., Ltd. is a large-scale modern private pharmaceutical enterprise integrating research, production, and marketing of proprietary Chinese medicines, chemical pharmaceuticals, and biological pharmaceuticals, as well as pharmaceutical chain operations and standardized cultivation of Chinese herbal materials.
 

　　Neptunus Group: Revenue Approaches 60 Billion
 

Neptunus Group recorded sales of nearly RMB 60 billion in 2018, ranking among the top enterprises in China’s pharmaceutical industry by comprehensive strength. Focusing on the pharmaceutical and health sectors, the company is striving to achieve its development goal of annual sales exceeding RMB 200 billion at an early date, thereby entering the Fortune Global 500.
 

Public information indicates that Neptunus Group is a leading comprehensive pharmaceutical and healthcare enterprise group in China with a full industry chain.